Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions.

Kokjohn TA, Roher AE.

Alzheimers Dement. 2009 Jul;5(4):340-7. doi: 10.1016/j.jalz.2009.03.002. Review.

2.

Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.

Rockenstein E, Torrance M, Mante M, Adame A, Paulino A, Rose JB, Crews L, Moessler H, Masliah E.

J Neurosci Res. 2006 May 15;83(7):1252-61.

PMID:
16511867
3.

Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role in Alzheimer's disease.

Dodson SE, Andersen OM, Karmali V, Fritz JJ, Cheng D, Peng J, Levey AI, Willnow TE, Lah JJ.

J Neurosci. 2008 Nov 26;28(48):12877-86. doi: 10.1523/JNEUROSCI.4582-08.2008.

4.

APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis.

Crews L, Rockenstein E, Masliah E.

Brain Struct Funct. 2010 Mar;214(2-3):111-26. doi: 10.1007/s00429-009-0232-6. Epub 2009 Nov 29. Review.

5.

Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease.

Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C, March A, Ait-Ghezala G, Mullan MJ.

J Neuroinflammation. 2010 Mar 8;7:17. doi: 10.1186/1742-2094-7-17.

6.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
7.

Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain.

Wu G, Miller RA, Connolly B, Marcus J, Renger J, Savage MJ.

Neurodegener Dis. 2014;14(2):53-66. doi: 10.1159/000353634. Epub 2013 Oct 23.

PMID:
24158021
8.

The type of Aβ-related neuronal degeneration differs between amyloid precursor protein (APP23) and amyloid β-peptide (APP48) transgenic mice.

Rijal Upadhaya A, Scheibe F, Kosterin I, Abramowski D, Gerth J, Kumar S, Liebau S, Yamaguchi H, Walter J, Staufenbiel M, Thal DR.

Acta Neuropathol Commun. 2013 Nov 18;1:77. doi: 10.1186/2051-5960-1-77.

9.

Dispersible amyloid β-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice.

Rijal Upadhaya A, Capetillo-Zarate E, Kosterin I, Abramowski D, Kumar S, Yamaguchi H, Walter J, Fändrich M, Staufenbiel M, Thal DR.

Neurobiol Aging. 2012 Nov;33(11):2641-60. doi: 10.1016/j.neurobiolaging.2011.12.032. Epub 2012 Feb 2.

PMID:
22305478
10.

[Alzheimer disease: cellular and molecular aspects].

Octave JN.

Bull Mem Acad R Med Belg. 2005;160(10-12):445-9; discussion 450-1. French.

PMID:
16768248
11.

Rho-associated protein kinase 1 (ROCK1) is increased in Alzheimer's disease and ROCK1 depletion reduces amyloid-β levels in brain.

Henderson BW, Gentry EG, Rush T, Troncoso JC, Thambisetty M, Montine TJ, Herskowitz JH.

J Neurochem. 2016 Aug;138(4):525-31. doi: 10.1111/jnc.13688. Epub 2016 Jul 1.

12.

Interactions between amyloid-β and hemoglobin: implications for amyloid plaque formation in Alzheimer's disease.

Chuang JY, Lee CW, Shih YH, Yang T, Yu L, Kuo YM.

PLoS One. 2012;7(3):e33120. doi: 10.1371/journal.pone.0033120. Epub 2012 Mar 6.

13.

Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice.

Aliev G, Seyidova D, Lamb BT, Obrenovich ME, Siedlak SL, Vinters HV, Friedland RP, LaManna JC, Smith MA, Perry G.

Neurol Res. 2003 Sep;25(6):665-74.

PMID:
14503022
14.

Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.

van Groen T, Kiliaan AJ, Kadish I.

Neurobiol Dis. 2006 Sep;23(3):653-62. Epub 2006 Jul 10.

PMID:
16829076
15.

Reduction of β-amyloid accumulation by reticulon 3 in transgenic mice.

Araki W, Oda A, Motoki K, Hattori K, Itoh M, Yuasa S, Konishi Y, Shin RW, Tamaoka A, Ogino K.

Curr Alzheimer Res. 2013 Feb;10(2):135-42.

PMID:
22742855
16.

Amyloid precursor protein-induced axonopathies are independent of amyloid-beta peptides.

Stokin GB, Almenar-Queralt A, Gunawardena S, Rodrigues EM, Falzone T, Kim J, Lillo C, Mount SL, Roberts EA, McGowan E, Williams DS, Goldstein LS.

Hum Mol Genet. 2008 Nov 15;17(22):3474-86. doi: 10.1093/hmg/ddn240. Epub 2008 Aug 11.

17.
18.

Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss.

Takeuchi A, Irizarry MC, Duff K, Saido TC, Hsiao Ashe K, Hasegawa M, Mann DM, Hyman BT, Iwatsubo T.

Am J Pathol. 2000 Jul;157(1):331-9. Erratum in: Am J Pathol 2000 Oct;157(4):1413.

19.

Lesion of the subiculum reduces the spread of amyloid beta pathology to interconnected brain regions in a mouse model of Alzheimer's disease.

George S, Rönnbäck A, Gouras GK, Petit GH, Grueninger F, Winblad B, Graff C, Brundin P.

Acta Neuropathol Commun. 2014 Feb 11;2:17. doi: 10.1186/2051-5960-2-17.

20.

Baicalein reduces β-amyloid and promotes nonamyloidogenic amyloid precursor protein processing in an Alzheimer's disease transgenic mouse model.

Zhang SQ, Obregon D, Ehrhart J, Deng J, Tian J, Hou H, Giunta B, Sawmiller D, Tan J.

J Neurosci Res. 2013 Sep;91(9):1239-46. doi: 10.1002/jnr.23244. Epub 2013 May 17.

Supplemental Content

Support Center